A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

This is an early-phase (Phase 1) study testing a new experimental treatment called UB-VV111 — alone and combined with a drug called rapamycin — in patients whose B-cell blood cancers (such as large B-cell lymphoma or chronic lymphocytic leukemia) have come back or stopped responding to prior treatments. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL) - Your disease is measurable on scans or tests - You have no serious other medical conditions **You may NOT be eligible if...** - Your cancer is not a CD19-positive B-cell cancer - You have serious active infections or organ problems - Your disease is not measurable or evaluable - You are unable to give voluntary informed consent Talk to your doctor to see if this trial is right for you.